Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | BCMA-CD38 bispecific CAR-T cells in R/R MM

Yu Hu, MD, PhD, Huazhong University of Science and Technology, Wuhan, China, presents the updated results from a phase 1 dose-climbing trial (ChiCTR1800018143). This trial investigated a bispecific CAR T-cell therapy targeting BCMA and CD38 in patients with relapsed or refractory multiple myeloma (MM), evaluating the safety, efficacy and duration of BM38 T-cells. The initial data provide strong evidence to support the further development of the dual-target CAR-T therapy for relapsed/refractory MM. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.